Ontology highlight
ABSTRACT:
PROVIDER: PRJNA482768 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR7591654_1.fastq.gz | Fastqsanger.gz | |||
| SRR7591654_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 2 of 2 |
Similar Datasets
Project description:Nitrogen fixation is an important metabolic process carried out by microorganisms, which converts molecular nitrogen into inorganic nitrogenous compounds such as ammonia (NH3). These nitrogenous compounds are crucial for biogeochemical cycles and for the synthesis of essential biomolecules, i.e. nucleic acids, amino acids and proteins. Azotobacter vinelandii is a bacterial non-photosynthetic model organism to study aerobic nitrogen fixation (diazotrophy) and hydrogen production. Moreover, the diazotroph can produce biopolymers like alginate and polyhydroxybutyrate (PHB) that have important industrial applications. However, many metabolic processes such as partitioning of carbon and nitrogen metabolism in A. vinelandii remain unknown to date.
Genome-scale metabolic models (M-models) represent reliable tools to unravel and optimize metabolic functions at genome-scale. M-models are mathematical representations that contain information about genes, reactions, metabolites and their associations. M-models can simulate optimal reaction fluxes under a wide variety of conditions using experimentally determined constraints. Here we report on the development of a M-model of the wild type bacterium A. vinelandii DJ (iDT1278) which consists of 2,003 metabolites, 2,469 reactions, and 1,278 genes. We validated the model using high-throughput phenotypic and physiological data, testing 180 carbon sources and 95 nitrogen sources. iDT1278 was able to achieve an accuracy of 89% and 91% for growth with carbon sources and nitrogen source, respectively. This comprehensive M-model will help to comprehend metabolic processes associated with nitrogen fixation, ammonium assimilation, and production of organic nitrogen in an environmentally important microorganism.
2023-03-10 | MODEL2204190001 | BioModels
Project description:Interventions: Case vs control:No
Primary outcome(s): High-throughput sequencing
Study Design: Case-Control study
| 2676067 | ecrin-mdr-crc
Project description:The aim of this study was to extend our analysis to the obligate human pathogen M. tuberculosis, which has to deal with a more restricted set of environmental variables in terms of nitrogen sources, and to delineate the GlnR regulon, by peforming global analysis of GlnR-DNA interactions by Chromatin Immunoprecipitation and high-throughput sequencing (ChIP-seq) over nitrogen run-out.
2014-12-01 | E-MTAB-2492 | biostudies-arrayexpress
Project description:Interventions: left hemicolectomy:None;right hemicolectomy:None;sigmoid resection:None;radical rectal cancer:None;low rectal resection with prophylactic ileostomy:None
Primary outcome(s): Fecal high-throughput sequencing;Fecal Metabolomics;immunomics
Study Design: Factorial
| 85716 | ecrin-mdr-crc
Project description:High-throughput RNA sequencing of methanosarcina grown on methylated sulfur compounds
| PRJNA270832 | ENA
Project description:We developed a general approach to small molecule library screening called GE-HTS (Gene Expression-Based High Throughput Screening) in which a gene expression signature is used as a surrogate for cellular states and applied it to the identification of compounds inducing the differentiation of acute myeloid leukemia cells. In screening 1,739 compounds, we identified 8 that reliably induced the differentiation signature, and furthermore yielded functional evidence of bona fide differentiation. This SuperSeries is composed of the following subset Series:; GSE976: Gene Expression-Based High Throughput Screening: APL Treatment with Candidate Compounds; GSE982: Gene Expression-Based High Throughput Screening: HL-60 Cell Treatment with Candidate Compounds; GSE983: Gene Expression-Based High Throughput Screening: Primary Patient AML Blasts, Normal Neutrophils, and Normal Monocytes; GSE985: Gene Expression-Based High Throughput Screening: HL-60 Cells Treated with ATRA and PMA Experiment Overall Design: Refer to individual Series
2007-09-20 | E-GEOD-995 | biostudies-arrayexpress
Project description:Considering the multi-targeting potential of furan-indole hybrids as anticancer agents, this study aimed to unveil the mechanism of new 3-(2-furoyl)-indole derivatives for their cytotoxicy on hepatocellular carcinoma cells. Initially, we conducted an in vitro cytotoxicity assay for thirteen 3-(2-furoyl)-indole derivatives on HepG2 and MCF-7 cells using MTT assay, correlating the results with in silico screening of the selected drug targets. Among them, compounds 4a, 4b, and 4c demonstrated better selectivity towards HepG2 cells than MCF-7 cells. This was in good agreement with docking studies, which showed the high binding affinity of compound 4a to the Chain A of IGF-1R at Ile1160, Glu 1080, Met 1082 and Asp-1086, similar to reference ligand. Molecular dynamic study inferred the stable and high binding affinity of compound 4a to IGF-1R. The RMSD and RMSF values were found to be acceptable, and accordingly, a pharmacophore model was constructed. Hence, we conducted label-free quantitative proteome profiling of HepG2 cells treated with active compounds using an in-solution trypsin digestion procedure followed by high-resolution mass spectrometric analysis. We noticed that compound 4a targets IGF-1R pathway by dysregulation of proteins such as SHC-transforming protein 1(P29353), Mitogen-activated protein kinase kinase 3 isoform B variant (Q53EZ9), dual specificity mitogen-activated protein kinase kinase 4 (P45985), stress-activated protein kinase JNK (A0A286YF97), and mitogen-activated protein kinase (E9PQW4). In addition, the apoptotic activities of 4a, 4b, and 4c were studied against HepG2 cells using FACS. These findings are in good agreement with our in silico results, proteome profiling, and also earlier reports on indole compounds. Furthermore, we predicted the in silico ADMET property of the compounds.
2026-03-09 | PXD054680 | Pride
Project description:High-throughput screen of natural compounds and biomarkers for NSCLC
| PRJNA682345 | ENA